Madrigal Pharmaceuticals
MDGL
42 hedge funds and large institutions have $33.3M invested in Madrigal Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 9 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
41% more capital invested
Capital invested by funds: $23.6M → $33.3M (+$9.74M)
31% more funds holding
Funds holding: 32 → 42 (+10)
3.6% more ownership
Funds ownership: 13.22% → 16.82% (+3.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$4.92M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.13M |
| 3 |
BlackRock
New York
|
+$2.54M |
| 4 |
AC
Armistice Capital
New York
|
+$2.41M |
| 5 |
State Street
Boston,
Massachusetts
|
+$518K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$6.7M |
| 2 |
Millennium Management
New York
|
-$486K |
| 3 |
Goldman Sachs
New York
|
-$321K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$181K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$148K |
MDGL Hedge Fund Activity: Q2 2017 in Review
42 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q2 2017, worth a combined $33.3M — up 41% from $23.6M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MDGL positions and 9 closed out — a net gain of 10 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was Rock Springs Capital Management, adding an estimated $4.92M. The largest seller was Capital World Investors, exiting entirely with an estimated $6.7M sold.
- 42 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q2 2017, up from 32 in Q1 2017.
- Funds reported $33.3M of Madrigal Pharmaceuticals stock for Q2 2017, up 41% quarter-over-quarter.
- 19 funds opened new Madrigal Pharmaceuticals positions in Q2 2017 and 9 closed out, a net change of +10 holders.
- The largest Madrigal Pharmaceuticals buyer in Q2 2017 was Rock Springs Capital Management, an estimated $4.92M added.
- The largest Madrigal Pharmaceuticals seller in Q2 2017 was Capital World Investors, an estimated $6.7M sold.
Based on aggregated 13F filings for Q2 2017.